RecruitingPhase 1NCT06013995
A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus
Studying Chronic cutaneous lupus erythematosus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bristol-Myers Squibb
- Principal Investigator
- Bristol-Myers SquibbBristol-Myers Squibb
- Intervention
- BMS-986326(drug)
- Enrollment
- 44 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2023 – 2026
Study locations (27)
- Local Institution - 0048, San Diego, California, United States
- Clinical Research of West Florida, Inc. (Clearwater), Clearwater, Florida, United States
- Clinical Research of West Florida, Tampa, Florida, United States
- North Georgia Rheumatology, Lawrenceville, Georgia, United States
- Skin Sciences, Louisville, Kentucky, United States
- Local Institution - 0062, Las Vegas, Nevada, United States
- Columbia University Irving Medical Center, New York, New York, United States
- Local Institution - 0005, Duncansville, Pennsylvania, United States
- Allen Arthritis, Allen, Texas, United States
- Metroplex Clinical Research Center, Dallas, Texas, United States
- Arthritis Northwest, PLLC, Spokane, Washington, United States
- Hospital Universitario Austral, Pilar, Buenos Aires, Argentina
- Clinica Adventista Belgrano, CABA, Buenos Aires F.D., Argentina
- Local Institution - 0072, Sofia, Bulgaria
- Local Institution - 0044, Berlin, Germany
- +12 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06013995 on ClinicalTrials.govOther trials for Chronic cutaneous lupus erythematosus
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07355218A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)EMD Serono Research & Development Institute, Inc.
- RECRUITINGPHASE2NCT06980805A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)Immunovant Sciences GmbH
- ENROLLING BY INVITATIONPHASE3NCT06044337A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusBiogen